CareDx, Inc
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG006JS5785
CDNA
CareDx, Inc
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Diagnostics & Research
NAME
CareDx, Inc
ISIN
US14167L1035
TICKER
CDNA
MIC
XNAS
REUTERS
CDNA.OQ
BLOOMBERG
CDNA US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Tue, 11.03.2025
CareDx
US14167L1035
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that AlloSure® is now commercially available for pediatric heart transplant ...
Tue, 04.03.2025
CareDx
US14167L1035
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA).
CareDx provides medical services and tests for transplant recipients with notable products AlloSure, AlloMap, and RemoTraC. On October...
Wed, 26.02.2025
CareDx
US14167L1035
CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024.
Fourth Quarter Financial Highlights
Revenue of $86.6 million, increased 32% year-over-year
Testing services revenue of $63.8 million, increased 37% year-over-year, and testing services volume of approximately 45,500, i...
Tue, 25.02.2025
CareDx
US14167L1035
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the District Court overturned the jury verdict in patent litigation brought by a competitor.
The District Co...
Fri, 21.02.2025
CareDx
US14167L1035
Johnson Fistel, LLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws.
What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certai...
Thu, 20.02.2025
CareDx
US14167L1035
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings published in Transplant International1 that show the performance of...
Thu, 13.02.2025
CareDx
US14167L1035
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new AlloHeme data presented at the 2025 Tandem Meetings, Transplantation &am...
Tue, 11.02.2025
CareDx
US14167L1035
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, Februar...
Mon, 13.01.2025
CareDx
US14167L1035
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.
Preliminary Fourth Quarter 2024 Financial Results
Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year.
Testi...
Wed, 18.12.2024
CareDx
US14167L1035
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan He...
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
